Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
Ferring Pharmaceuticals and Boehringer Ingelheim Japan on July 15 launched their newly listed therapies Adstiladrin (nadofaragene firadenovec) and Jascayd (nerandomilast), while Taiho Pharmaceutical said the PI3Kα inhibitor Haizexin (risovalisib) will go on sale on July 28. Adstiladrin, a non-replicating gene…
To read the full story
Related Article
BUSINESS
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
- AstraZeneca Sees Broad Pipeline, AI Powering 50-Plus Approval Goal
August 5, 2026
- Voyxact PIII Data Confirm Kidney Function Stabilization in IgAN
August 5, 2026
- Perioperative Imfinzi Seen Advancing Gastric Cancer Care: Oncologist
August 5, 2026
- Teijin Still Seeking “Best Owner” for Legacy Drug Portfolio
August 5, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…